Editor-in-Chief Hatice Kübra Elçioğlu Vice Editors Levent Kabasakal Esra Tatar Online ISSN 2630-6344 Publisher Marmara University Frequency Bimonthly (Six issues / year) Abbreviation J.Res.Pharm. Former Name Marmara Pharmaceutical Journal
Author Guidelines

Copyright Transfer Agreement Form (pdf) | Copyright Transfer Agreement Form (docx)

Manuscript Template

Author Checklist Form

2.2.        REVIEW ARTICLES (by invitation only)
2.3.        COMMENTARIES
3.1.1.         Contribution to Editorial Decision
3.1.2.         Confidentiality
3.1.3.         Disclosure and  conflicts of interest
3.1.4.         Standards of Objectivity
3.1.5.         Procedures for Dealing With Unethical Behaviour
3.2.1.         Contribution to Editorial  Decision and Promptness
3.2.2.         Confidentiality
3.2.3.         Standards of Objectivity
3.2.4.         Acknowledgement of Source  and Disclosure and Conflicts of Interest
3.3.1.         Reporting standards and Data Access and Retention
3.3.2.         Originality and Plagiarism 

3.3.3.         Multiple, Redundant or Concurrent Publication
3.3.4.         Hazards and Human or Animal Subjects
3.3.5.         Acknowledgement of Sources and Disclosure, Conflicts of Interest
3.3.6.         Fundamental errors in published works
5.1.        TITLE
5.2.1.         Present/permanent address
5.2.2.         Corresponding Author
5.3.        ABSTRACT
5.4.        KEY WORDS
5.5.        INTRODUCTION
5.6.1.         Results
5.6.2.         Discussion
5.7.        CONCLUSIONS
5.8.1.         Characterization of the synthesized compounds
5.12.          REFERENCES
5.12.1.      Citation in text
5.12.2.      Web references
5.12.3.      Formatting
5.12.4.      Examples
5.13.          TABLES
5.14.          FIGURES
5.14.1. Image manipulation
9.       REVISIONS
9.1. Changes to authorship
10.1. Online proof correction


Journal of Research in Pharmacy is the official scientific journal of Marmara University Faculty of Pharmacy. The journal is the continuation of the former "Journal of Pharmacy of University of Marmara" which was published between 1985 and 1997. Since 2010, the journal has been published online four times a year (January, April, July and October). It is an open access, peer-reviewed journal devoted to the publication of papers in pharmacy and pharmaceutical sciences. The journal publishes content in English. The journal aims at providing a medium for the dissemination of interdisciplinary papers of interest for many different specialists.
Journal of Research in Pharmacy publishes original research articles, review articles and scientific commentaries on all aspects of pharmaceutical sciences depending on their conceptual novelty and scientific quality. The journal welcomes articles in this multidisciplinary field, with a focus on topics relevant for drug action, drug discovery and development, conventional and emerging fields related to pharmaceutical sciences. Articles, which cannot be associated with pharmaceutical issues in any way, might be returned to authors without processing. Scientific commentaries and review articles are generally evaluated by invitation or assent of the Editors. Proceedings of scientific meetings may also be published as special issues or supplements to the Journal, upon decision by the editors.
Manuscripts submitted to Journal of Research in Pharmacy are only accepted on the comprehension that (I) they are subject to editorial review (at least by two independent referees); (II) they have not been, and will not be fully or partially published elsewhere; (III) the recommendations of the most recent version of the Declaration of Helsinki, for humans, and the European Community guidelines as accepted principles for the use of experimental animals have been adhered to. The Journal of Research in Pharmacyl will, therefore, only consider manuscripts that describe experiments which have been carried out under approval of an institutional or local ethics committee.
Journal of Research in Pharmacy serves  to further academic discussions of topics, irrespective of their nature –  whether religious, gender-based, environmental, ethical, political or other  potentially or topically contentious subjects and adopts a neutral position on  issues.   Publication of an article in our academic  peer-reviewed journal involves many parties, the author, the journal editor, the  peer-reviewer; each have responsibilities to meet expected ethical standards at  all stages in their involvement from submission to publication of an  article.  
Journal of Research in Pharmacy is committed to  meeting and upholding standards of International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the European Association of Science Editors (EASE), and National Information Standards Organization (NISO), Budapest Open Access Initiative (BOAI). The journal conforms to the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice)
Marmara University on behalf of which  it publishes shall ensure that good practice is maintained to the standards  outlined below. Articles are freely available to both subscribers and the wider public with permitted reuse. No open access publication fee, submission charge, and processing charge payable by authors or on their behalf, e.g. by their research funder or institution.
Journal of Research in Pharmacy supports Open Data.  After acceptance, articles  will be made publicly available on our journal’s website under Institutional Repository :dspace.marmara.edu.tr. Also, LOCKSS system has permission to collect, preserve, and serve this open access Archival Unit.


The Editor-in-Chief and one Editor, as well as members of the Journal's Editorial Advisory Board and independent experts, will review the manuscripts submitted to Journal of Research in Pharmacy. However, the Editor-in-Chief reserves the right to reject a manuscript without conducting an in-depth review if he/she feels that the manuscript is "out of scope" or it does not meet the minimal acceptance criteria for publication in Journal of Research in Pharmacy.


Research Articles are comprehensive accounts of significant and original experimental and/or theoretical results that fit within the scope of J. Res. Pharm. They contain innovative, hypothesis-driven research that is supported by sound experimental design, methodology, and data interpretation. Journal of Research in Pharmacy publishes research articles in the multidisciplinary field of pharmaceutical sciences. Authors are asked to write their manuscripts in a clear and concise manner. Preferably manuscripts should not exceed, 5,500 words of text and a total of 8 figures and/or tables. Extra experimental and/or theoretical data in the form of text, figures and tables should be deposited under Supplementary Material.

2.2.REVIEW ARTICLES (by invitation only)

Reviews provide a comprehensive summary of broadly-based topics of general interest to pharmaceutical scientists. Reviews are not limited as to the number of words, tables, figures and references that may be included. Unsolicited reviews are considered only if they are authored by investigators who have demonstrated expertise in the relevant areas. An author interested in preparing a Review for J. Res. Pharm. should provide the title, abstract and a brief outline to Prof. İlkay Küçükgüzel requesting an invitation to submit a manuscript in this category.


These articles contain topical issues of public and scientific interest; and summarize the viewpoints of distinguished pharmaceutical scientists with regard to the current status and future direction of the field. Commentaries are usually published by invitation only. An author interested in preparing a commentary for J. Res. Pharm., should provide a brief outline to Prof. İlkay Küçükgüzel requesting an invitation to submit a manuscript in this category.


This type of manuscript discusses important parts, overlooked aspects, or lacking parts of a previously published article. Articles on subjects within the scope of the journal that might attract the readers’ attention, particularly educative cases, may also be submitted in the form of a “Letter to the Editor.” Readers can also present their comments on the published manuscripts in the form of a “Letter to the Editor”.  Abstract, Keywords, and Tables, Figures, Images, and other media should not be included. The text should be unstructured. The article that is being commented on, must be properly cited within this manuscript.

3.    BEFORE YOU BEGIN 3.1. EDITORS’ RESPONSIBILITIES 3.1.1.     Contribution to Editorial Decision  

The Editor is responsible  for deciding which of the papers submitted to the journal should be published.  The editor may confer with the members of the Editorial Board or reviewers in  making this decision.  
The editor may reject a manuscript  without additional opinions if it is deemed to be (a) inappropriate as to  subject matter or format; (b) of poor quality; or (c) of inadequate  significance. This decision, based primarily on the manuscript as submitted,  should take into account the editor’s assessment of the possible impact of  revisions by the author.
Editor should endeavor to  select reviewers who possess appropriate expertise and exercise sound judgment.  All manuscripts are generally submitted to 2-3 reviewers and supplementary material may be included to facilitate the review process. Editor then should ensure that the reviewers understand their responsibilities,  including those regarding confidentiality and the timely preparation of an  unbiased review. Members of the editorial board will usually be called upon for advice when there is disagreement among the reviewers or between reviewers and authors, or when the editors feel that the manuscript has not received adequate consideration by the reviewers.
 The Editor should provide the corresponding author with a copy of the  reviewers’ comments regarding a manuscript. Before forwarding a reviewer’s  comments to an author, the editor may delete any inappropriately harsh language  or personal attacks included in the review. The need for these deletions should  be brought to the attention of the reviewer. Such language or attacks should  not influence the editor's decision regarding the manuscript, although it may  require the editor to seek input from an additional reviewer.
The editor should correct errors in a manuscript if they are detected before publication  or publish corrections if they are detected afterwards. All notices of  correction or retraction must be published prominently in the journal in which  the original report appeared and contain the full bibliographic reference to  the original article or abstract. It should also be listed in the contents page  and be prominently labeled (e.g., erratum, retraction, or apologia).
The editor is under no  obligation to reconsider a manuscript she/he has rejected. However, an editor  may offer the authors an opportunity to respond to criticisms and/or to prepare  a revised version. In this case, the editor should permit the authors a  reasonable but limited period of time in which to do so.
The editor should hold  authors to a high standard with regard to the citation of appropriate  literature, emphasizing the use of initial, peer-reviewed references whenever  possible. However, an editor should not encourage authors to cite the editors’  journal merely to enhance that journal’s reputation.
The editor should handle submissions for  sponsored supplements or special issues in the same way as other submissions,  so that articles are considered and accepted solely on their academic merit and  without commercial influence.

3.1.2.     Confidentiality    

The Editor and the members of the Editorial Board must  not disclose any information about a submitted paper to anyone other than the  authors of the paper, reviewers, potential reviewers, and the publisher, as  appropriate.
In the case where authors have a  conflict of interest, the editor may request that the authors include a  statement to this effect in the manuscript before it can be reviewed or  accepted for publication.    

3.1.3.     Disclosure and  conflicts of interest      
Unpublished materials disclosed in a submitted paper  will not be used in the own research of the Editor or the members of the  Editorial Board without the express written consent of the author.   


3.1.4.     Standards of Objectivity    

The editor should act in a balanced, objective  and fair way while carrying out their expected duties, without discrimination  on grounds of gender, sexual orientation, religious or political beliefs,  ethnic or geographical origin of the authors.
The editor should adopt and follow reasonable  procedures in the event of complaints of an ethical or conflict nature, in  accordance with the policies and procedures of the Society where  appropriate to give authors a reasonable opportunity to respond to any  complaints. All complaints should be investigated no matter when the  original publication was approved. Documentation associated with any such  complaints should be retained.

3.1.5.     Procedures for Dealing With Unethical Behaviour    

Misconduct and unethical behaviour may be identified  and brought to the attention of the editor and publisher at any time, by  anyone. Whoever informs the editor or publisher of such conduct should provide  sufficient information and evidence in order for an investigation to be  initiated. All allegations should be taken seriously and treated in the  same way, until a successful decision or conclusion is reached.
The editor   should  gather evidences, while  avoiding spreading any allegations beyond those who need to know. Minor  misconduct might be dealt with without the need to consult more widely and the  author should be given the opportunity to respond to any allegations. The editor  should inform the author or reviewer where there appears to be a  misunderstanding or misapplication of acceptable standards as a warning to  future behaviour.
Serious misconduct or a case of  plagiarism comes to light after a paper is published; these cases might require that the employers  of the accused be notified. The editor should make the decision whether or  not to involve the employers, either by examining the available evidence itself  or by further consultation with a limited number of experts. The editor should  inform the author, the head of the author’s and reviewer’s department and  funding agency, abstracting & indexing services and the readership of the  publication concurrently with formal retraction or withdrawal of the  publication from the journal. The editor should lay a formal embargo on  contributions from an individual for a defined period.


3.2.1.     Contribution to Editorial  Decision and Promptness    

The reviewer should contribute to the  decision-making process, and to assist in improving the quality of the  published paper by reviewing the manuscript objectively.
The reviewer receives an  invitation to review a manuscript at a time when circumstances preclude prompt  attention to it, the reviewer should decline the invitation in a timely manner.  The reviewer should submit his/her evaluation of the manuscript in a timely  manner.
The reviewer should  consider the quality and significance of the experimental and theoretical work,  the completeness of the description of methods and materials, the logical basis  of the interpretation of the results, and the exposition with due regard to the  maintenance of high standards of communication. Reviews should include  constructive suggestions for revision, including, if appropriate, indication of  where statements may require additional reference to the published literature.
The reviewers should  comment tactfully. Harsh language and personal attacks on the authors are  unacceptable; they also may call into question the validity of the reviewer's  comments. 
An individual who is asked  to review a manuscript and who feels inadequately qualified to judge that  manuscript should return the manuscript promptly without review and advise the  editor of  the circumstances.

3.2.2.     Confidentiality    

The reviewer should maintain the  confidentiality of any information supplied by the editor or author. The  reviewer should  not retain or copy the  manuscript.
The Reviewer should not  use any information, arguments, or interpretations contained in a manuscript  under consideration to advance their research unless the information has been  made publicly available through another source, such as an abstract or a  presentation at a meeting, a stock offering, or a new article.

3.2.3.     Standards of Objectivity    

The reviewer should not communicate with authors about a manuscript under  consideration. Likewise, authors should not initiate such a communication with  a reviewer but instead should communicate only with the editor. If an author  persists in attempting to communicate with a reviewer, that reviewer should  notify the editor.

3.2.4.     Acknowledgement of Source  and Disclosure and Conflicts of Interest    

The reviewer should be aware of any potential  conflicts of interest (financial, institutional, collaborative or other  relationships between the reviewer and author) and to alert the editor to  these, if necessary withdrawing their services for that manuscript.


The  corresponding (submitting) author is solely responsible for communicating with  the journal and with managing communication between coauthors. Before  submission, the corresponding author ensures that all authors are included in  the author list, its order has been agreed by all authors, and that all authors  are aware that the paper was submitted. The responsibility for all aspects of manuscript preparation rests with the authors. Extensive changes or rewriting of the manuscript is not the responsibility of the Editors.
Journal of Research in Pharmacy also allows up to two co-corresponding authors to be specified as having contributed equally to the work or having jointly supervised the work. Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.
The corresponding author is  welcome to suggest suitable independent reviewers when he/she submit his/her  manuscript, but the suggestion may not be followed by the journal.
All reviewers' comments must be responded to, and suggested changes be made. The author should detail the changes made in response to the referees' comments and suggestions in an accompanying letter. If the author disagrees with some changes, the reason, supported by data, should be given.
The editors may refuse to publish manuscripts from authors who persistently ignore referees' comments. A revised manuscript should be received by the editorial office no later than 2 months after the editorial decision was sent to the author(s); otherwise it will be processed as a new manuscript.
After acceptance, the proof is  sent to the corresponding author, who circulates it to all coauthors and deals  with the journal on their behalf; the journal will not necessarily correct  errors after publication if they result from errors that were present on a  proof that was not shown to coauthors before publication. The corresponding  author is responsible for the accuracy of all content in the proof, in  particular that names of coauthors are present and correctly spelled, and that  addresses and affiliations are current. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.
Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

3.3.1.     Reporting standards and Data Access and Retention    

Authors should maintain accurate records of  data associated with their submitted manuscript, and to supply or provide  access to these data, on reasonable request. Where appropriate and where  allowed by employer, funding body and others who might have an interest, to deposit  data in a suitable repository or storage location, for sharing and further use  by others.

3.3.2.     Originality and Plagiarism    

Authors should confirm that all the work in the  submitted manuscript is original and to acknowledge and cite content reproduced  from other sources. The authors should obtain the written consent of the copyright-holder to reproduce any content (pictures, schemes, figures etc) from other sources (journals, books); and the authors should provide the editor with the permission.
To verify originality, your article will be checked by the plagiarism detection software iThenticate.

3.3.3.     Multiple, Redundant or Concurrent Publication    

Authors should confirm/assert that the  manuscript as submitted is not under consideration or accepted for publication  elsewhere and if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. Where portions of the content overlap with published or  submitted content, to acknowledge and cite those  sources. Additionally,  authors  should provide the editor with a copy of any submitted manuscript that might  contain overlapping or closely related content.

3.3.4.     Hazards and Human or Animal Subjects    

Authors should ensure that any studies  involving human or animal subjects conform to national, local and institutional  laws and requirements and confirm that approval has been sought and obtained  where appropriate. Authors should obtain express permission from human  subjects and respect their privacy. Unless the authors have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and visual elements) must be removed before submission.
When reporting experiments on  human subjects, authors should indicate, in methods section whether the  procedures followed were in accordance with the ethical standards of the  responsible committee on human experimentation (institutional and national) and  with the Helsinki Declaration of 2008, http://www.wma.net/ en/30publications/ 10policies/b3/17c.pdf.  Manuscripts that report the results of experimental investigation with human  subjects must include a statement that informed consent was obtained after the  procedure(s) had been fully explained. In the case of children, authors are  asked to include information about whether the child's assent was obtained in  addition to that of the legal guardian.
When reporting experiments on animals,  authors should indicate whether the institutional and national guides for the  care and use of laboratory animals were followed as in "Guide for the Care  and Use of Laboratory Animals" (www.nap.edu/ catalog/5140.html). The authors must mention  in the methods section of the manuscript that they had performed the study in  accordance with above-mentioned rules and, in the case of humans, emphasize  that they had received informed consent from the participants.

3.3.5.     Acknowledgement of Sources and Disclosure, Conflicts of Interest    

Authors should declare any potential conflicts of interest (e.g. where  the author has a competing interest (real or apparent) that could be considered  or viewed as exerting an undue influence on his or her duties at any stage  during the publication process).

3.3.6.     Fundamental errors in published works

Authors should notify promptly the journal editor  or publisher if a significant error in their publication is identified. To  cooperate with the editor and publisher to publish an erratum, addendum,  corrigendum notice, or to retract the paper, where this is deemed necessary. 


J. Res. Pharm. uses an online article submission and management system for peer reviewing and tracking purposes. Manuscripts must be submitted online by the corresponding author at jrespharm.com. You may be required to register as a new user with Editorial management system upon your first visit. Straightforward sign in and registration procedures can be found on the website. Editorial management system allows authors to track the progress of manuscript review in real time. Detailed, step-by-step instructions for submitting manuscripts can be found on the website. All correspondence regarding your manuscript must go through our online editorial management system.
Manuscripts can only be submitted through the journal’s online manuscript submission and evaluation system, available at jrespharm.com. Manuscripts submitted via any other medium will not be evaluated.
Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal’s guidelines. Submissions that do not conform to the journal’s guidelines will be returned to the submitting author with technical correction requests.


Authors must use our manuscript template which is accessible at our website and article submission system (https://www.jrespharm.com/static.php?id=7). This will facilitate manuscript preparation and may prevent delays due to returning of your article at technical check stage. Manuscripts should contain the following elements in the following order:
Author names, affiliations
Materials and Methods
Authorship statement
Conflict of interest statement

Tables and figures should be placed where they are related, not in a separate section at the end of the article.

5.1. TITLE

Title should be concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae, where possible. Titles are of great importance for current awareness and for information retrieval. The wording of titles should be chosen carefully to provide information on the contents and to function as "points of entry" for information retrieval. Symbols, formulas, or arbitrary abbreviations should not be included in the title, except chemical symbols to indicate the structure of isotopically labeled compounds. Full title must be in sentence case. The title of the manuscript must be written in lower case except for the first word and proper nouns.


Author names must be given in full, with surnames (family names) all in capitals.
Where names may be ambiguous (e.g., a double name, or possible confusion about first/last names), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript number immediately after the author's name and in front of the appropriate address. Author addresses must be given in English in the following order: Department, Faculty, University, City, Country, with numbers in superscript after each author name to indicate his/her address.  Provide the full postal address of each affiliation, including the country name for each author.

5.2.1.     Present/permanent address

If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

5.2.2.     Corresponding Author

You should designate one author to act as corresponding author. Note that this is the person who will receive correspondence from Journal of Research in Pharmacy editorial office and needs to be the person who will appear as corresponding author on the paper if accepted.
The manuscript has to be submitted online by the person who is in charge of correspondence at all stages of the editorial process, production, and post-publication. Ensure that phone/fax numbers with country and area codes) are provided, in addition to the e-mail address (preferably an institutional e-mail address) and the complete postal address. Contact details of the other authors must be kept up to date by the corresponding author.


A concise and factual abstract, which is unstructured, is required. The abstract is limited to 250 words or less for research and review articles and, 200 words or less for commentaries. The abstract should state briefly the purpose of the research, experimental approach, the principal results and major conclusions. An abstract is often presented separately from the article, so the text should be comprehensible when read alone. For this reason, references should be avoided.
The use of numbers in the abstract identifying compounds, formulas, tables or references and non-standard or uncommon abbreviations should be avoided. However, if essential, they must be defined at their first mention in the abstract.


Each submission must be accompanied by a minimum of four to a eight keywords that reflect the scientific content of your manuscript for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible.


In this section, the authors should state the objectives of the work, define the scope of your paper, summarize relevant work to the study being reported and provide an adequate background. A detailed literature survey or a summary of the results should be avoided. It should not be a review of the subject area, but should finish with a clear statement of the question being addressed. The introduction must be designed to inform the reader of the rationale and significance of the study.



Results should be clear and concise. Text, tables and figures must show minimal overlap, and must be internally consistent. Tables and figures should be designed to maximize the presentation and comprehension of the experimental data. Attention should be paid to the matter of significant figures (usually, no more than three). The same data should not be presented in more than one figure or in both a figure and a table. As a rule, interpretation of the results should be reserved for the discussion section of a Research Article, but under some circumstances it may be desirable to combine results and discussion in a single section.

5.6.2.     Discussion

The Results and Discussion sections may be combined. Avoid extensive citations and discussion of published literature. The purpose of the discussion is to interpret significance of the results and to relate them to existing knowledge in the field in as clear and brief a fashion as possible. Information given elsewhere in the manuscript should not be repeated in the discussion. Extensive reviews of the literature should be avoided.


The main conclusions of the study should be presented in a short Conclusions section, which stands alone. You should explain whether your findings supported your hypothesis. Avoid using references in conclusion section.


Methods already published should be indicated by a reference: only relevant modifications should be described.
The experimental procedures should be described in sufficient detail to enable others to repeat the experiments. Names of products and manufacturers (with locations) should be supplied for all mentioned equipment, instruments, chemicals, etc. Brand names may be used only once in the manuscript. For subsequent designation, use "formulation A", product B", etc. Novel experimental procedures should be described in detail, but published procedures should merely be referred to by literature citation of both the original and any published modifications. The purity of key compounds and descriptions(s) of the method(s) used to determine purity should be included in this section. For buffers, use terminology such as "20 mM potassium phosphate buffer (pH 7.7) containing...". Also, state w/v or v/v when appropriate. Identification of and precautions for handling hazardous chemicals and dangerous procedures should be placed at the beginning of the section. An example would be " Caution: The following chemicals are hazardous and should be handled carefully; (list of chemicals and handling procedures or references) ". Manuscripts containing data generated from animal and/or human studies must specify the committee and the institution that approved the experimental protocols used to generate these data.

5.8.1.     Characterization of the synthesized compounds

Sufficient experimental information should be given by the authors. A melting point range should be reported for every crystalline solid product, together with the solvent from which it was recrystallized, and a description of the material e.g. “yellow needles, mp 123-124  ºC (from ethanol)”. For all synthesized compounds (new or previously reported), evidence to confirm both identity and purity have to be provided. Evidence for the identity of new compounds should include both elemental analysis and 1H NMR data. 13C NMR data of at least some key structures should be present. Evidence for the identity of new compounds should include, 1H NMR data and either HRMS (resolution 0.001 m/z unit or better) or elemental analysis data to support the molecular formula assignment. In case HRMS is preferred to elementel analysis, HPLC chromatograms should be provided as supplementary material.
To facilitate reviewing process, the authors are encouraged to submit a list of compounds as a separate file. In this list, previously reported and new compounds should be classified. Chemical structures and SMILES codes of all compounds should be supplied, together with the names of the characterization techniques used for each compound. This form should be uploaded as Supplementary material (for reviewing purposes only).


Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. This section should acknowledge financial support, help from a lab technician or statistician, advice from colleagues, gifts, etc. Permission must be received from persons whose contribution to the work is acknowledged in the manuscript.

5.10.               AUTHORSHIP STATEMENT

Author contributions should be written right before conflict of interest statement, in accordance with JRP – Copyright Transfer Agreement signed by the authors. Please use initials instead of full names. It should appear as follows :
Author contributions: Concept – İ.K., E.T.; Design – İ.K., E.T.; Supervision – E.T.; Resource – İ.K.; Materials – N.K., A.D.; Data Collection &/or Processing - N.K., A.D.; Analysis &/or Interpretation - N.K., A.D.; Literature Search – İ.K., E.T., N.K., A.D.; Writing – E.T., İ.K.; Critical Reviews – İ.K., E.T., N.K., A.D.


Journal of Research in Pharmacy requires and encourages the authors and the reviewers involved in the evaluation process of submitted manuscripts to disclose any existing or potential conflicts of interests, including financial, consultant, and institutional, that might lead to potential bias or a conflict of interest. Any financial grants or other support received for a submitted study from individuals or institutions should be disclosed to the Editorial Board.
If there is no conflict of interest to be declared by any of the authors, write “The authors declared no conflict of interest” in the manuscript.

5.12.               REFERENCES 5.12.1.   Citation in text

While citing publications, preference should be given to the latest, most up-to-date publications. References should conform to Vancouver style and be numbered consecutively in the order in which they are cited in the text. Cite in the text by the appropriate Arabic numeral enclosed in square brackets, e.g., [1], [2-5], etc. Authors are responsible for the accuracy of references. All references cited in the manuscript must appear in the list of references at the end and all references listed in the reference list must be cited in the manuscript. Do not include personal communications, unpublished data, or other unpublished materials as references. In the case of cited publications in languages other than English, the published English title should be provided if one exists, with an annotation such as “(article in Turkish with an abstract in English)”. If the publication was not published with an English title, provide the original title only; do not provide a self-translation.

5.12.2.   Web references

Although web references is not recommended by Journal of Research in Pharmacy, some circumstances might be considered as exceptional cases. These are: Websites of governmental organizations (ie. ministries of health, FDA), international organizations (ie. WHO, EMA, ICH, EFMC), online calculation tools (ie. Molinspiration, VCCLAB).

5.12.3.  Formatting

Journal titles should be abbreviated in accordance with the journal abbreviations in Thomson Reuters Web of Science, Index Medicus/ MEDLINE/PubMed. For all journal articles (including articles in press) in the reference list, the DOI numbers should be provided (ie. http://dx.doi.org/10.1016/j.ejmech.2016.05.017). The reference styles for different types of publications are presented in the following examples.

5.12.4.  Examples

Reference to a journal publication:

[1] Tatar E, Küçükgüzel İ, Daelemans D, Talele TT, Kaushik-Basu N, De Clercq E, Pannecouque C. Some hydrazones of 2-aroylamino-3-methylbutanohydrazide: synthesis, molecular modeling studies, and identification as stereoselective inhibitors of HIV-1. Arch Pharm (Weinheim). 2013; 346(2): 140-153. http://dx.doi.org/10.1002/ardp.201200311.

[2] Tatar E, Karakuş S, Küçükgüzel ŞG, Öktem Okullu S, Ünübol N, Kocagöz T, De Clercq E, Andrei G, Snoeck R, Pannecouque C, Kalaycı S, Şahin F, Sriram D, Yogeeswari P, Küçükgüzel İ. Design, synthesis, and molecular docking studies of a conjugated thiadiazole-thiourea scaffold as antituberculosis agents. Biol Pharm Bull. 2016; 39(4): 502-515. http://dx.doi.org/10.1248/bpb.b15-00698.

[3] Kulabaş N, Bingöl Özakpınar Ö, Özsavcı D, Leyssen P, Neyts J, Küçükgüzel İ. Synthesis, characterization and biological evaluation of thioureas, acylthioureas and 4-thiazolidinones as anticancer and antiviral agents. J Res Pharm. 2017; 21(2): 371-384. http://dx.doi.org/10.12991/marupj.300913.

Reference to a book:

2.    Silverman RB, The Organic Chemistry of Drug Design and Drug Action, third ed., Elsever, Burlington, MA, USA 2014.
Reference to a chapter in an edited book:

3.    Şener G, Sakarcan A, Yeğen B. Melatonin as a radioprotective agent. In: Montilla P, Túnez I. (Eds). Melatonin: Present and Future. Nova Science Publishers, Inc., New York, 2008, pp.127-142.


4.    Tatar E. PhD Thesis. Synthesis and characterization of novel 1,3-thiazolidine-4-ones derived from 2-(aroylamino)-3-methyl butyric acid hydrazide. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Haydarpaşa, İstanbul, Turkey, 2009.
Reference to a website:

5.    VCCLAB, Virtual Computational Chemistry Laboratory. http://www.vcclab.org (accessed March 18, 2017).

6.    PASS (Prediction of Activity Spectra for Substances) program. http://www.way2drug.com/passonline(accessed July 18, 2015).

7.    WHO Global tuberculosis report 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf?ua=1, (accessed July 18, 2015).

  5.13.     TABLES

Please submit tables as editable text and not as images. Tables should be placed next to the relevant text in the article. They should not be given on separate page(s) after the references. Number tables consecutively in accordance with their appearance in the text and place any table footnotes below the table body. Table headings should be given above the table and written in sentence case. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

5.14.     FIGURES

All artworks, figures, images, illustrations, graphics, photos, pictures, plots and schemes should be labeled as Figures. Figures must be submitted both in the manuscript and as separate files. Inclusion of the figures in the manuscript should be done using add pictures command under insert tab – do NOT use copy and paste function. All tables and figures must have a caption and/or legend and be numbered (e.g., Table 1, Figure 2), unless there is only one table or figure, in which case it should be labelled “Table” or “Figure” with no numbering. Captions must be written in sentence case (e.g., Physical and spectral data of the synthesized compounds.). The font used in the figures should be Times New Roman. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
All tables and figures must be numbered consecutively as they are referred to in the text. Please refer to tables and figures with capitalisation and unabbreviated (e.g., “As shown in Figure 2…”, and not “Fig. 2” or “figure 2”). The tables and figures themselves should be given in the running text. They should not be given at the end of the text only, after the references.
To ensure the highest print quality, your figures should be submitted in either TIFF or JPEG format at the highest possible resolution (300 dpi or higher). The authors should obtain written permission from the respective publishers to reproduce any images from other sources, even if they are quoted from their previous papers.

5.14.1. Image manipulation

Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.
Please do not:

  • Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
  • Supply files that are too low in resolution;
  • Submit graphics that are disproportionately large for the content.

Table 1. Limitations of JRP for each manuscript type.


Word limit
(main text only)

Word limit (Abstract)

Reference limit

Table limit

Figure limit

Keyword limit

Research Article

max. 5500


Max. 80

Max. 8

Max. 8


Review Article

No limits


Min. 50

No limits

No limits



max. 2500


Max. 30

Max. 4

Max. 4

Max. 6

Letter to Editor

max. 1000

No abstract

Max. 10

No tables

No figures

No keywords


6.            NOMENCLATURE

It is the responsibility of the authors to provide correct nomenclature.
Only generic and chemical names of drugs should be used, although a proprietary equivalent may be indicated once, only in materials and methods section. Formally adopted nonproprietary names listed in the International Nonproprietary Names (INN), approved by the World Health Organization, should be used.
The nomenclature of chemical substances should be consistent, clear and unambiguous, and should conform to the usage of the American Chemical Society and the convention recommended by the International Union of Pure and Applied Chemistry (IUPAC). When in doubt, writers should consult the indexes of Chemical Abstracts; the various reports and pamphlets of the American Chemical Society Committee on Nomenclature, Spelling and Pronunciation; and from the International Union of Biochemistry and Molecular Biology (IUBMB): Biochemical Nomenclature and Related Documents (Portland Press, London).


If symbols such as ×, α, β, γ, δ, λ, µ, η, or ν are used, they should be added using the Symbol menu of Word. Degree symbols (°) must be used from the Symbol menu, not superscripted letter o or number 0. Multiplication symbols must be used (×), not the letter x. Spaces must be inserted between numbers and units (e.g., 10 mg) and between numbers and mathematical symbols (+, –, ×, =, <, >), but not between numbers and percent symbols (e.g., 95%). Please use SI units.
All non-standard or uncommon abbreviations and acronyms should be kept to a minimum and should be defined at their first mention. Latin terms such as et al., in vitro, or in situ should not be italicised. However, Latin binary names of plants, animals and microorganisms should be written in italics, and genus names should be capitalized (eg. Atropa belladonaMus musculusStaphylococcus aureus).   
The preferred forms for some of the more commonly used abbreviations are mp, bp, TLC, GC, HPLC, UPLC, 1H NMR, 13C NMR, GC-MS, LC-MS, LC-MS/MS, HRMS, FAB HRMS, UV, IR, FTIR, DNase, ED50, ID50, IC50, LD50, mRNA, RNase, rRNA, tRNA, cpm, Ci,  Vmax, Km, k, t1/2, AMP, ADP, ATP (and their cytidine, guanosine, thymidine, uridine analogues), Cyp, FAD, NAD+, NADH, NADP+, NADPH, GSH, GSSG.
Units should be abbreviated without punctuation and with no distinction between singular and plural forms (e.g., 1 ml, 50 ml). Abbreviations of units of measurements and other terms are as follows:
Units of mass
1 kilogram: kg,  gram: g, milligram: mg,  microgram: μg, nanogram: ng, mole (gram-molecule): mol, millimole: mmol,  micromole: μmol, nanomole: nmol, picomole: pmol, femtomole: fmol, equivalent: eq
Units of time
1 hour: h,  minute: min,  second: s, millisecond: ms,  microsecond: μs
Units of volume
1 litre: l,  millilitre: ml, microlitre: μl
Units of length
1 metre: m, centimetre: cm,  millimetre: mm, micrometre: μm, nanometre: nm
Units of concentration
1 molar (mol/l): M, millimolar: mM, micromolar: μM,  nanomolar: nM, picomolar: pM, parts per million: ppm
Units of heat, energy, electricity
1 Joule: J, degree Celsius (centigrade): °C, Coulomb: C, Ampere: A, Volt: V, ohm: Ω,  Siemens: S
Units of radiation
1 curie: Ci,  counts per minute: cpm,  disintegrations per minute: dpm, becquerel: Bq
1 gravity: g, dissociation constant: Kd, median doses: LD50, ED50, probability P, routes of drug administration: i.v., i.p., s.c., i.m., square centimetre: cm2, standard deviation: S.D., standard error of the mean: S.E.M


Structural chemical formulas, process flow diagrams and complicated mathematical expressions should be very clearly presented. All subscripts, superscripts, Greek letters and unusual characters must be identified.
All chemical structures and reaction schemes should be produced by the authors. Quotation of these material from other sources (journals, books, websites etc.) is not accepted. Chemical formulas and reaction schemes should be drawn using a molecule editor such as ChemSketch or ChemDraw. Structure drawing style of these softwares should be set to ACS. When using this style, it is authors’s choice to show the terminal carbons or not. Produced structures should be saved as TIFF or JPEG images and embedded into main word document (at the end of the document) using insert image function of MS word. All chemical structures and reaction schemes should be labeled as Figures (Figure 1,2 etc.).
For inclusion of a mathematical formula, use equation add-on feature of MS Word under insert tab in the symbols group (MS Word > insert > symbols > equation). Do not use quotations from other documents as images and do not insert mathematical equations as images. Present simple formulae in the line of normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).
 Presentation of equations in the text line:
 (Eq. 1)            log(1/C)= −k1(log P)2 + k2 log k3                      
 Presentation of equations produced by MS Word equation add-on:


Supplementary material such as images, tables, detailed experimental procedures, chromatographic and spectral findings (text), can be published with your article to enhance it. All supplementary items should be submitted in a single PDF document. Submitted supplementary items are published exactly as they are received. Please submit your material together with the article and supply a concise, descriptive caption. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version. All tables and figures in the supplementary materials, should be labeled in such a way (ie. Table S1, Figure S1) to avoid confusion with those in the manuscript file.

9.            REVISIONS

When submitting a revised version of a paper, the author must submit a detailed “Response to the reviewers” that states point by point how each issue raised by the reviewers has been covered and where it can be found (each reviewer’s comment, followed by the author’s reply and line numbers where the changes have been made) as well as an annotated copy of the main document. Revised manuscripts must be submitted within 60 days from the date of the decision letter. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be canceled. If the submitting author(s) believe that additional time is required, they should request this extension before the initial 60-day period is over.
Accepted manuscripts are copy-edited for grammar, punctuation, and format. Once the publication process of a manuscript is completed, it is published online on the journal’s webpage as “articles in press” before it is included in its scheduled issue. A PDF proof of the accepted manuscript is sent to the corresponding author and their publication approval is requested within 2 days of their receipt of the proof. Inclusion or replacement of new data or author names at this point is not allowed.

9.1. Changes to authorship

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Addition, deletion or rearrangement of authors after submission and even acceptance of a paper are not welcome by the editorial board. It may result in rejection of the paper, if the editor are not convinced about reliability and necessity of this action.  Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.



10.1. Online proof correction

Corresponding authors will receive an e-mail with an online link to your proofs. You should choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors. We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely the authors’ responsibility.

Marmara University